Research Papers:

A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population

Jacek Marzec _, Xueying Mao, Meiling Li, Meilin Wang, Ninghan Feng, Xin Gou, Guomin Wang, Zan Sun, Jianfeng Xu, Hua Xu, Xiaoping Zhang, Shan-Chao Zhao, Guoping Ren, Yongwei Yu, Yudong Wu, Ji Wu, Yao Xue, Bo Zhou, Yanling Zhang, Xingxing Xu, Jie Li, Weiyang He, Sara Benlloch, Helen Ross-Adams, Li Chen, Jucong Li, Yingqia Hong, Zsofia Kote-Jarai, Xingang Cui, Jianguo Hou, Jianming Guo, Lei Xu, Changjun Yin, Yuanping Zhou, David E. Neal, Tim Oliver, Guangwen Cao, Zhengdong Zhang, Douglas F. Easton, Claude Chelala, The PRACTICAL Consortium, The CHIPGECS Group, Ali Amin Al Olama, Rosalind A. Eeles, Hongwei Zhang and Yong-Jie Lu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:21393-21403. https://doi.org/10.18632/oncotarget.7250

Metrics: PDF 3010 views  |   HTML 3044 views  |   ?  


Jacek Marzec1,*, Xueying Mao1,*, Meiling Li2,*, Meilin Wang3,*, Ninghan Feng4,5,*, Xin Gou6,*, Guomin Wang7,*, Zan Sun8,*, Jianfeng Xu9,10,*, Hua Xu11,*, Xiaoping Zhang12,*, Shan-Chao Zhao13, Guoping Ren14, Yongwei Yu15, Yudong Wu16, Ji Wu17, Yao Xue3, Bo Zhou18, Yanling Zhang14, Xingxing Xu2, Jie Li6, Weiyang He6, Sara Benlloch19, Helen Ross-Adams20, Li Chen12, Jucong Li13, Yingqia Hong13, Zsofia Kote-Jarai21, Xingang Cui22, Jianguo Hou23, Jianming Guo7, Lei Xu7, Changjun Yin5, Yuanping Zhou24, David E. Neal20, Tim Oliver1, Guangwen Cao2, Zhengdong Zhang3, Douglas F. Easton19, Claude Chelala1, The PRACTICAL Consortium, The CHIPGECS Group, Ali Amin Al Olama19, Rosalind A. Eeles21,25, Hongwei Zhang2, Yong-Jie Lu1

1Centre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK

2Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China

3Department of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, 210029, China

4Department of Urology, Wuxi Second People’s Hospital, Nanjing Medical University, Wuxi, 214002, China

5Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China

6Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China

7Department of Urology, Zhongshan Hospital, Fudan University Medical College, Shanghai, 200032, China

8Liaoning People’s Hospital and Center of Experiment and Technology, China Medical University, Shenyang, 110001, China

9Program for Personalized Cancer Care, North Shore University Health System, Evanston, IL 60201, U.S.A

10Fudan Institute of Urology, Huashang Hospital, Fudan University, Shanghai, 200040, China

11Department of Urology, Tongji Hospital, Huazhong Science and Technology University, Wuhan, 430030, China

12Department of Urology, Xiehe Hospital, Huazhong Science and Technology University, Wuhan, 430022, China

13Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

14Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, 310009, China

15Department of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China

16Department of Urology, First Affiliated Hospital, Medical College, Zhengzhou University, Zhengzhou, 450003, China

17Department of Urology, North Sichuan Medical College, Nanchong, 637000, China

18Department of Nutrition Science, Shenyang Medical College, Shenyang, 110034, China

19Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge–Strangeways Research Laboratory, Cambridge, CB1 8RN, UK

20Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK

21Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK

22Department of Urology, Changzheng Hospital, The Second Military Medical University, Shanghai, 200003, China

23Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China

24Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

25The Royal Marsden NHS Foundation Trust, London and Surrey, SM2 5NG, UK

*These authors have contributed equally to this work

Correspondence to:

Yong-Jie Lu, e-mail: [email protected]

Hongwei Zhang, e-mail: [email protected]

Keywords: Chinese prostate cancer, genetic risk, single-nucleotide polymorphism, predisposition, population difference

Received: September 02, 2015     Accepted: January 23, 2016     Published: February 8, 2016


Prostate cancer predisposition has been extensively investigated in European populations, but there have been few studies of other ethnic groups. To investigate prostate cancer susceptibility in the under-investigated Chinese population, we performed single-nucleotide polymorphism (SNP) array analysis on a cohort of Chinese cases and controls and then meta-analysis with data from the existing Chinese prostate cancer genome-wide association study (GWAS). Genotyping 211,155 SNPs in 495 cases and 640 controls of Chinese ancestry identified several new suggestive Chinese prostate cancer predisposition loci. However, none of them reached genome-wide significance level either by meta-analysis or replication study. The meta-analysis with the Chinese GWAS data revealed that four 8q24 loci are the main contributors to Chinese prostate cancer risk and the risk alleles from three of them exist at much higher frequencies in Chinese than European populations. We also found that several predisposition loci reported in Western populations have different effect on Chinese men. Therefore, this first extensive single-nucleotide polymorphism study of Chinese prostate cancer in comparison with European population indicates that four loci on 8q24 contribute to a great risk of prostate cancer in a considerable large proportion of Chinese men. Based on those four loci, the top 10% of the population have six- or two-fold prostate cancer risk compared with men of the bottom 10% or median risk respectively, which may facilitate the design of prostate cancer genetic risk screening and prevention in Chinese men. These findings also provide additional insights into the etiology and pathogenesis of prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7250